You are here

  • Home
  • Archive
  • Volume 31, Issue Suppl 3
  • 40 InnovaTV 301/ENGOT-cx12/GOG-3057: tisotumab vedotin vs investigator’s choice chemo in second- or third-line recurrent or metastatic cervical cancer

Citation Tools

Article menu

Download PDFPDF

Cervical cancer
40 InnovaTV 301/ENGOT-cx12/GOG-3057: tisotumab vedotin vs investigator’s choice chemo in second- or third-line recurrent or metastatic cervical cancer
Free

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Vergote I, Randall L, Kalbacher E, et al
40 InnovaTV 301/ENGOT-cx12/GOG-3057: tisotumab vedotin vs investigator’s choice chemo in second- or third-line recurrent or metastatic cervical cancer
International Journal of Gynecologic Cancer 2021;31:A1.